CRBP-300-196.png
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
July 25, 2018 09:20 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
CRBP-300-196.png
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
July 20, 2018 09:20 ET | Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference
June 21, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
The New York Academy of Sciences symposium will highlight cutting edge research across the fields of inflammation, infection, and tissue regeneration, with focus on novel resolution mediators and...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference
June 14, 2018 08:25 ET | Corbus Pharmaceuticals Holdings, Inc.
- Live fireside chat webcast on Wednesday, June 20th at 2:30 p.m. EDT - Norwood, MA, June 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the...
CRBP-300-196.png
Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018
June 13, 2018 09:29 ET | Corbus Pharmaceuticals Holdings, Inc.
Multiple key efficacy outcomes further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies Lenabasum continues to demonstrate a favorable safety...
CRBP-300-196.png
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
June 06, 2018 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 24, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
May 10, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
– Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases – Norwood, MA, May 10, 2018 ...